Mohammad Reza Toliat

Mohammad Reza Toliat

Auto-generated profile, based on publicly available information

Mohammad Reza Toliat

Cologne Center for Genomics, University of Cologne, Cologne, Germany

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2015 in BMC Genomics
Verified
Journal Article
Open access
PDF file
AHAmir Hossini
Amir Hossini
MMMatthias Megges
Matthias Megges
Alessandro PrigioneAlessandro Prigione
Alessandro Prigione
BLBjoern Lichtner
Bjoern Lichtner
MTMohammad R Toliat
Mohammad R Toliat
James AdjayeJames Adjaye
James Adjaye
Alzheimer’s disease (AD) is a complex, irreversible neurodegenerative disorder. At present there are neither reliable markers to diagnose AD at an early stage nor therapy. To investigate underlying disease mechanisms, induced pluripotent stem cells (iPSCs) allow the generation of patient-derived neuronal cells in a dish. In this study, employing iPS technology, we derived and characterized iPSCs from dermal fibroblasts of an 82-year-old female patient affected by sporadic AD. The AD-iPSCs were differentiated into neuronal cells, in order to generate disease-specific protein association networks modeling the molecular pathology on the transcriptome level of AD, to analyse the reflection of the disease phenotype in gene expression in AD-iPS neuronal cells, in particular in the ubiquitin-proteasome system (UPS), and to address expression of typical AD proteins. We detected the expression of p-tau and GSK3B, a physiological kinase of tau, in neuronal cells derived from AD-iPSCs. Treatment of neuronal cells differentiated from AD-iPSCs with an inhibitor of γ-secretase resulted in the down-regulation of p-tau. Transcriptome analysis of AD-iPS derived neuronal cells revealed significant changes in the expression of genes associated with AD and with the constitutive as well as the inducible subunits of the proteasome complex. The neuronal cells expressed numerous genes associated with sub-regions within the brain thus suggesting the usefulness of our in-vitro model. Moreover, an AD-related protein interaction network composed of APP and GSK3B among others could be generated using neuronal cells differentiated from two AD-iPS cell lines. Our study demonstrates how an iPSC-based model system could represent (i) a tool to study the underlying molecular basis of sporadic AD, (ii) a platform for drug screening and toxicology studies which might unveil novel therapeutic avenues for this debilitating neuronal disorder.

15 April 2018 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
BSBrendon P. Scicluna
Brendon P. Scicluna
MWMaryse A. Wiewel
Maryse A. Wiewel
LVLonneke A. van Vught
Lonneke A. van Vught
AHArie J. Hoogendijk
Arie J. Hoogendijk
AKAugustijn M. Klarenbeek
Augustijn M. Klarenbeek
TPTom Van der Poll
Tom Van der Poll

11 April 2020 in Clinical Genetics
Verified
Journal Article
Open access
PDF file
BBBirgit Budde
Birgit Budde
MAMaha Abdelgaber Aly
Maha Abdelgaber Aly
MMMostafa R. Mohamed
Mostafa R. Mohamed
ABAndreas Breß
Andreas Breß
JAJanine Altmüller
Janine Altmüller
PNPeter Nürnberg
Peter Nürnberg
Nonsyndromic hearing loss is an extremely heterogeneous disorder. Thus, clinical diagnostics is challenging, in particular due to differences in the etiology of hearing loss between populations. With this study, we wanted to elucidate the genetic basis of hearing loss in 61 consanguineous Egyptian families. In 25 families, linkage analysis was used as a prescreening to identify regions for targeted sequencing of candidate genes. Initially, the coding regions of 12 and later of 94 genes associated with hearing loss were enriched and subjected to massively parallel sequencing (MPS) with diagnostic yields of 36% and 75%, respectively. Causative variants were identified in 48 families (79%). They were found in 23 different genes with the majority being located in MYO15A (15.3%), SLC26A4 (9.7%), GJB2 (8.3%), and MYO7A (6.4%). As many as 32 variants were novel ones at the time of detection. Five variants were shared by two, three, or even four families. Our study provides a first survey of the mutational spectrum of deaf patients in Egypt revealing less GJB2 variants than in many European populations. It underlines the value of targeted enrichment of well‐selected deafness genes in combination with MPS in the diagnostics of this frequent and genetically heterogeneous disorder.

1 November 2011 in Human Immunology
Verified
Journal Article
Closed access
Alexander Yaw DebrahAlexander Yaw Debrah
Alexander Yaw Debrah
LDLinda B. Debrah
Linda B. Debrah
AAAnna Albers
Anna Albers
SMSabine Mand
Sabine Mand
MTMohammad Reza Toliat
Mohammad Reza Toliat
KPKenneth Pfarr
Kenneth Pfarr


22 November 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
GAGhada M. H. Abdel-Salam
Ghada M. H. Abdel-Salam
SHSusanne Hellmuth
Susanne Hellmuth
EGElise Gradhand
Elise Gradhand
SKStephan Käseberg
Stephan Käseberg
JWJennifer Winter
Jennifer Winter
HBHanno J. Bolz
Hanno J. Bolz
MAD2L1BP -encoded p31 comet mediates Trip13-dependent disassembly of Mad2- and Rev7-containing complexes and, through this antagonism, promotes timely spindle assembly checkpoint (SAC) silencing, faithful chromosome segregation, insulin signaling, and homology-directed repair (HDR) of DNA double-strand breaks. We identified a homozygous MAD2L1BP nonsense variant, R253*, in 2 siblings with microcephaly, epileptic encephalopathy, and juvenile granulosa cell tumors of ovary and testis. Patient-derived cells exhibited high-grade mosaic variegated aneuploidy, slowed-down proliferation, and instability of truncated p31 comet mRNA and protein. Corresponding recombinant p31 comet was defective in Trip13, Mad2, and Rev7 binding and unable to support SAC silencing or HDR. Furthermore, C-terminal truncation abrogated an identified interaction of p31 comet with tp53. Another homozygous truncation, R227*, detected in an early-deceased patient with low-level aneuploidy, severe epileptic encephalopathy, and frequent blood glucose elevations, likely corresponds to complete loss of function, as in Mad2l1bp –/– mice. Thus, human mutations of p31 comet are linked to aneuploidy and tumor predisposition.